These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19443354)

  • 1. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.
    Sooriakumaran P; Coley HM; Fox SB; Macanas-Pirard P; Lovell DP; Henderson A; Eden CG; Miller PD; Langley SE; Laing RW
    Anticancer Res; 2009 May; 29(5):1483-8. PubMed ID: 19443354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer.
    Sooriakumaran P; Macanas-Pirard P; Bucca G; Henderson A; Langley SE; Laing RW; Smith CP; Laing EE; Coley HM
    Cancer Genomics Proteomics; 2009; 6(2):93-9. PubMed ID: 19451093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
    Narayanan BA; Narayanan NK; Pttman B; Reddy BS
    Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.
    Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
    Cancer; 2007 Feb; 109(3):588-97. PubMed ID: 17177201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study.
    Nery FG; Monkul ES; Hatch JP; Fonseca M; Zunta-Soares GB; Frey BN; Bowden CL; Soares JC
    Hum Psychopharmacol; 2008 Mar; 23(2):87-94. PubMed ID: 18172906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.
    Zheng X; Cui XX; Avila GE; Huang MT; Liu Y; Patel J; Kong AN; Paulino R; Shih WJ; Lin Y; Rabson AB; Reddy BS; Conney AH
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5480-7. PubMed ID: 17875778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
    Sinsakul M; Sika M; Rodby R; Middleton J; Shyr Y; Chen H; Han E; Lehrich R; Clyne S; Schulman G; Harris R; Lewis J
    Am J Kidney Dis; 2007 Dec; 50(6):946-51. PubMed ID: 18037095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents.
    Mehar A; Macanas-Pirard P; Mizokami A; Takahashi Y; Kass GE; Coley HM
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1181-7. PubMed ID: 18089846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
    Narayanan BA; Reddy BS; Bosland MC; Nargi D; Horton L; Randolph C; Narayanan NK
    Clin Cancer Res; 2007 Oct; 13(19):5965-73. PubMed ID: 17908994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot randomized phase II study of celecoxib in oral premalignant lesions.
    Papadimitrakopoulou VA; William WN; Dannenberg AJ; Lippman SM; Lee JJ; Ondrey FG; Peterson DE; Feng L; Atwell A; El-Naggar AK; Nathan CO; Helman JI; Du B; Yueh B; Boyle JO
    Clin Cancer Res; 2008 Apr; 14(7):2095-101. PubMed ID: 18381950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study.
    Falahatkar S; Mokhtari G; Pourreza F; Asgari SA; Kamran AN
    Urology; 2008 Oct; 72(4):813-6. PubMed ID: 18692876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib.
    Narayanan NK; Nargi D; Horton L; Reddy BS; Bosland MC; Narayanan BA
    Prostate; 2009 Feb; 69(2):133-41. PubMed ID: 18819100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib decreases Ki-67 proliferative index in active smokers.
    Mao JT; Fishbein MC; Adams B; Roth MD; Goodglick L; Hong L; Burdick M; Strieter ER; Holmes C; Tashkin DP; Dubinett SM
    Clin Cancer Res; 2006 Jan; 12(1):314-20. PubMed ID: 16397057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S; Robbins J; West CR; Nemeth MA
    Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats.
    Márquez-Rosado L; Trejo-Solís MC; García-Cuéllar CM; Villa-Treviño S
    J Hepatol; 2005 Oct; 43(4):653-60. PubMed ID: 16023763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis.
    Olivares C; Bilotas M; Buquet R; Borghi M; Sueldo C; Tesone M; Meresman G
    Hum Reprod; 2008 Dec; 23(12):2701-8. PubMed ID: 18716040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined action of celecoxib and ionizing radiation in prostate cancer cells is independent of pro-apoptotic Bax.
    Handrick R; Ganswindt U; Faltin H; Goecke B; Daniel PT; Budach W; Belka C; Jendrossek V
    Radiother Oncol; 2009 Mar; 90(3):413-21. PubMed ID: 19038466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract.
    Lai V; George J; Richey L; Kim HJ; Cannon T; Shores C; Couch M
    Head Neck; 2008 Jan; 30(1):67-74. PubMed ID: 17615567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemopreventive effect of celecoxib against DMBA-induced breast cancer and its mechanism].
    Kang HF; Wang XJ; Liu XX; Dai ZJ; Xue FJ; Xue XH
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1599-602. PubMed ID: 17121709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib: new indication. Ankylosing spondylitis: no pain justifies the use of a cox-2 inhibitor. Patients still exposed to unjustified risks.
    Prescrire Int; 2008 Jun; 17(95):106. PubMed ID: 18627117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.